Lista de obras - Laura Zanotti - Dominio Público Uruguay

A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial

artículo científico publicado en 2016

A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers

artículo científico publicado en 2016

Altered immunolocalization of heat-shock proteins in human peri-implant gingiva

artículo científico publicado en 2007

Apatinib for the treatment of gastric cancer

artículo científico publicado en 2016

Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?

artículo científico publicado en 2017

Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.

artículo científico

CDK4/6 inhibitors in HER2-positive breast cancer

artículo científico publicado en 2017

Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis

artículo científico publicado en 2013

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients

artículo científico publicado en 2011

Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.

artículo científico publicado en 2014

Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response

artículo científico publicado en 2015

Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma

artículo científico publicado en 2017

Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery

artículo científico publicado en 2015

Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy

artículo científico publicado en 2015

HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm

artículo científico publicado en 2011

HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study

artículo científico publicado en 2016

Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome

artículo científico publicado en 2012

Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response

artículo científico publicado en 2009

Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues

artículo científico publicado en 2014

Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.

artículo científico

Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials

artículo científico publicado en 2016

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

artículo científico publicado en 2013

Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer

artículo científico publicado en 2016

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis

artículo científico publicado en 2017

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy ⬇️

artículo científico publicado el 27 de junio de 2013

Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence

artículo científico publicado en 2009

MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.

artículo científico publicado en 2013

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition

scientific article published on 10 October 2016

Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?

artículo científico publicado en 2015

New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials

artículo científico publicado en 2016

No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.

artículo científico publicado en 2016

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

artículo científico publicado en 2016

Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis

artículo científico publicado en 2013

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management

artículo científico publicado en 2011

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials

artículo científico publicado en 2016

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients

artículo científico publicado en 2010

Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma

artículo científico publicado en 2012

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.

artículo científico publicado en 2017

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

scientific article published on 17 October 2019

Lista de obras de Laura Zanotti

A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial

A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers

Altered immunolocalization of heat-shock proteins in human peri-implant gingiva

Apatinib for the treatment of gastric cancer

Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?

Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.

CDK4/6 inhibitors in HER2-positive breast cancer

Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients

Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.

Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response

Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma

Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery

Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy

HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm

HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study

Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome

Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response

Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues

Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.

Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy ⬇️

Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence

MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition

Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?

New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials

No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients

Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy